Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
Lancet Neurol
    February 2025
  1. BLANQUIE O, Guizzaro L, Herold R, Haberkamp M, et al
    EU regulatory horizons for Alzheimer's disease.
    Lancet Neurol. 2025;24:96-97.
    >> Share

  2. MASTERS CL
    Should the preclinical stage of Alzheimer's disease be disclosed?
    Lancet Neurol. 2025;24:94-95.
    >> Share

    January 2025
  3. THE LANCET NEUROLOGY
    Bridging the diagnostic gap in Alzheimer's disease.
    Lancet Neurol. 2025;24:1.
    >> Share

    December 2024
  4. SCHWORER EK, Zammit MD, Wang J, Handen BL, et al
    Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.
    Lancet Neurol. 2024;23:1214-1224.
    >> Share

  5. HUNDAL H
    Frank Longo: taking on Alzheimer's disease.
    Lancet Neurol. 2024;23:1188.
    >> Share

  6. RAFII MS
    The amyloid clock: mapping Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2024;23:1173-1174.
    >> Share

    October 2024
  7. STIRRUPS R
    Navigating the roads ahead for Alzheimer's disease.
    Lancet Neurol. 2024;23:971.
    >> Share

  8. HYMAN BT
    Amyloid removal and the appearance of brain volume loss.
    Lancet Neurol. 2024;23:957-958.
    >> Share

  9. BELDER CRS, Boche D, Nicoll JAR, Jaunmuktane Z, et al
    Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.
    Lancet Neurol. 2024;23:1025-1034.
    >> Share

    September 2024
  10. THE LANCET NEUROLOGY
    The evolving paradigm of Alzheimer's disease diagnosis.
    Lancet Neurol. 2024;23:845.
    >> Share

    August 2024
  11. OHRY A
    Ezio Giacobini: a leader in Alzheimer's disease research.
    Lancet Neurol. 2024;23:768.
    >> Share

    July 2024
  12. SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al
    gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236.
    >> Share

  13. POTIER MC, Steiner H, Chavez-Gutierrez L
    Amyloid beta, gamma-secretase, and familial Alzheimer's disease.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00292.
    >> Share

    June 2024
  14. KAPASI A, Schneider JA
    Speculation on the transmissibility of Alzheimer's disease.
    Lancet Neurol. 2024;23:555-556.
    >> Share

    May 2024
  15. WISCH JK, McKay NS, Boerwinkle AH, Kennedy J, et al
    Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2024;23:500-510.
    >> Share

  16. NORDBERG A
    Insights into the progression of genetic Alzheimer's disease from tau PET.
    Lancet Neurol. 2024;23:453-454.
    >> Share

    March 2024
  17. FRISONI GB, Festari C, Massa F, Cotta Ramusino M, et al
    European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.
    Lancet Neurol. 2024;23:302-312.
    >> Share

  18. THE LANCET NEUROLOGY
    Dementia diagnosis in the anti-amyloid era.
    Lancet Neurol. 2024;23:219.
    >> Share

    February 2024
  19. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    >> Share

  20. REIMAN EM, Cummings JL, Langbaum JB, Mattke S, et al
    A chance to prevent Alzheimer's disease sooner than you think.
    Lancet Neurol. 2024;23:144-145.
    >> Share

  21. BEJANIN A, Villain N
    Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.
    Lancet Neurol. 2024;23:127-128.
    >> Share

    January 2024
  22. DELRIEU J, Andrieu S, Vellas B
    Dementia research in 2023: the year of anti-amyloid immunotherapy.
    Lancet Neurol. 2024;23:13-15.
    >> Share

    December 2023
  23. RANSCOMBE P
    Powerful series profiles rare forms of dementia.
    Lancet Neurol. 2023;22:1112.
    >> Share

    November 2023
  24. SCHLEPCKOW K, Morenas-Rodriguez E, Hong S, Haass C, et al
    Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
    Lancet Neurol. 2023;22:1048-1060.
    >> Share

    September 2023
  25. JAGUST WJ, Teunissen CE, DeCarli C
    The complex pathway between amyloid beta and cognition: implications for therapy.
    Lancet Neurol. 2023;22:847-857.
    >> Share

    July 2023
  26. BELDER CRS, Schott JM, Fox NC
    Preparing for disease-modifying therapies in Alzheimer's disease.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00274.
    >> Share

  27. FRISONI GB
    Complexity is the simple truth about Alzheimer's disease.
    Lancet Neurol. 2023 Jul 13:S1474-4422(23)00176.
    >> Share

    June 2023
  28. THE LANCET NEUROLOGY
    Treatment for Alzheimer's disease: time to get ready.
    Lancet Neurol. 2023;22:455.
    >> Share

  29. MASON M, Bacioglu M, Vivacqua G, Spillantini MG, et al
    Targeting tau degradation: a viable therapeutic approach?
    Lancet Neurol. 2023;22:462-464.
    >> Share

    May 2023
  30. LANGWORTH-GREEN C, Patel S, Jaunmuktane Z, Jabbari E, et al
    Chronic effects of inflammation on tauopathies.
    Lancet Neurol. 2023;22:430-442.
    >> Share

    February 2023
  31. MEAD S, Fox NC
    Lecanemab slows Alzheimer's disease: hope and challenges.
    Lancet Neurol. 2023;22:106-108.
    >> Share

    January 2023
  32. BOERWINKLE AH, Gordon BA, Wisch J, Flores S, et al
    Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2023;22:55-65.
    >> Share

  33. FORTEA J, Quiroz YT, Ryan NS
    Lessons from Down syndrome and autosomal dominant Alzheimer's disease.
    Lancet Neurol. 2023;22:5-6.
    >> Share

    November 2022
  34. HARDY J, de Strooper B, Escott-Price V
    Diabetes and Alzheimer's disease: shared genetic susceptibility?
    Lancet Neurol. 2022;21:962-964.
    >> Share

    October 2022
  35. JACK CR JR
    Advances in Alzheimer's disease research over the past two decades.
    Lancet Neurol. 2022;21:866-869.
    >> Share

    May 2022
  36. OSSENKOPPELE R, van der Kant R, Hansson O
    Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Lancet Neurol. 2022 May 25. pii: S1474-4422(22)00168.
    >> Share

    April 2022
  37. MORENAS-RODRIGUEZ E, Li Y, Nuscher B, Franzmeier N, et al
    Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Lancet Neurol. 2022;21:329-341.
    >> Share

  38. SMIRNOV D, Galasko D
    Dynamics of neuroinflammation in Alzheimer's disease.
    Lancet Neurol. 2022;21:297-298.
    >> Share

    February 2022
  39. CHHATWAL JP, Schultz SA, McDade E, Schultz AP, et al
    Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
    Lancet Neurol. 2022;21:140-152.
    >> Share

  40. FRISONI GB, Lathuiliere A
    From patients to disease: the difficult case of Alzheimer's.
    Lancet Neurol. 2022;21:105-106.
    >> Share

    January 2022
  41. KANTARCI K
    2021 marks a new era for Alzheimer's therapeutics.
    Lancet Neurol. 2022;21:3-4.
    >> Share

    December 2021
  42. MEAD S, Evans T
    Safe laboratory management of prions and proteopathic seeds.
    Lancet Neurol. 2021;20:981.
    >> Share

    November 2021
  43. TEUNISSEN CE, Verberk IMW, Thijssen EH, Vermunt L, et al
    Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
    Lancet Neurol. 2021 Nov 24. pii: S1474-4422(21)00361.
    >> Share

  44. FORTEA J, Zaman SH, Hartley S, Rafii MS, et al
    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.
    Lancet Neurol. 2021;20:930-942.
    >> Share

  45. KEHOE PG, Turner N, Howden B, Jarutyte L, et al
    Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2021;20:895-906.
    >> Share

  46. DECARLI C
    The link between blood pressure and Alzheimer's disease.
    Lancet Neurol. 2021;20:878-879.
    >> Share

    September 2021
  47. THIJSSEN EH, La Joie R, Strom A, Fonseca C, et al
    Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Lancet Neurol. 2021;20:739-752.
    >> Share

  48. PARNETTI L, Filippo MD, Gaetani L
    A blood test for Alzheimer's disease: a step forward.
    Lancet Neurol. 2021;20:691-693.
    >> Share

    August 2021
  49. FAGAN AM, Henson RL, Li Y, Boerwinkle AH, et al
    Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2021;20:615-626.
    >> Share

  50. FRISONI GB, Hansson O
    Management of Alzheimer's disease takes a leap forward.
    Lancet Neurol. 2021;20:586-587.
    >> Share

  51. CARMONA-IRAGUI M, Alcolea D, Barroeta I, Videla L, et al
    Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Lancet Neurol. 2021;20:605-614.
    >> Share

    July 2021
  52. THE LANCET NEUROLOGY
    A contentious FDA ruling for Alzheimer's disease.
    Lancet Neurol. 2021 Jul 5. pii: S1474-4422(21)00215.
    >> Share

  53. BURNS DK, Alexander RC, Welsh-Bohmer KA, Culp M, et al
    Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:537-547.
    >> Share

    April 2021
  54. DUBOIS B, Villain N, Frisoni GB, Rabinovici GD, et al
    Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00066.
    >> Share

  55. JAGUST WJ
    The changing definition of Alzheimer's disease.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00077.
    >> Share

    March 2021
  56. GRAFF-RADFORD J, Yong KXX, Apostolova LG, Bouwman FH, et al
    New insights into atypical Alzheimer's disease in the era of biomarkers.
    Lancet Neurol. 2021;20:222-234.
    >> Share

    January 2021
  57. SERRANO-POZO A, Das S, Hyman BT
    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
    Lancet Neurol. 2021;20:68-80.
    >> Share

  58. KIVIPELTO M, Mangialasche F
    Dementia research in 2020: moving forward despite the COVID-19 pandemic.
    Lancet Neurol. 2021;20:3-5.
    >> Share

  59. THE LANCET NEUROLOGY
    Rapid drug access and scientific rigour: a delicate balance.
    Lancet Neurol. 2021;20:1.
    >> Share

    November 2020
  60. CHETELAT G, Arbizu J, Barthel H, Garibotto V, et al
    Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
    Lancet Neurol. 2020;19:951-962.
    >> Share

  61. ISAACS JD, Boenink M
    Biomarkers for dementia: too soon for routine clinical use.
    Lancet Neurol. 2020;19:884-885.
    >> Share

    October 2020
  62. LAUWERS E, Lalli G, Brandner S, Collinge J, et al
    Potential human transmission of amyloid beta pathology: surveillance and risks.
    Lancet Neurol. 2020;19:872-878.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016